Fostul ministru al S\u0103n\u0103t\u0103\u021bii, Vlad Voiculescu, propune o variant\u0103 controversat\u0103 pentru achitarea datoriei de aproximativ 600 de milioane de euro c\u0103tre Pfizer: nu bani, ci medicamente \u201einovatoare\u201d pentru pacien\u021bii rom\u00e2ni.<\/p>\n
Declara\u021bia ridic\u0103 semne serioase de \u00eentrebare, \u00een condi\u021biile \u00een care Rom\u00e2nia ajunge, practic, s\u0103 negocieze plata unei datorii uria\u0219e prin introducerea accelerat\u0103 a unor tratamente noi pe pia\u021ba intern\u0103.<\/p>\n
Datorie pl\u0103tit\u0103 \u201e\u00een natur\u0103\u201d<\/p>\n
Voiculescu sus\u021bine c\u0103 statul rom\u00e2n ar putea transforma datoria \u00een acces la:<\/p>\n
medicamente oncologice<\/p>\n
terapii pentru boli rare<\/p>\n
tratamente de ultim\u0103 genera\u021bie<\/p>\n
Toate furnizate de Pfizer, la pre\u021buri preferen\u021biale sau compensate din suma datorat\u0103.<\/p>\n
Ideea este prezentat\u0103 drept o oportunitate pentru sistemul medical, dar \u00een realitate deschide o dezbatere sensibil\u0103: devine Rom\u00e2nia un teren de testare pentru produse farmaceutice \u201einovatoare\u201d, \u00een schimbul unei datorii?<\/p>\n
Critici la adresa guvernului<\/p>\n
Fostul ministru atac\u0103 actuala conducere a Ministerului S\u0103n\u0103t\u0103\u021bii, \u00een special pe Alexandru Rafila, acuz\u00e2nd c\u0103 neasumarea unei decizii \u00een 2023 a dus la pierderi de sute de milioane de euro.<\/p>\n
Potrivit acestuia, o renegociere ar fi redus semnificativ costurile, \u00eens\u0103 statul rom\u00e2n a ajuns \u00een instan\u021b\u0103 \u0219i risc\u0103 acum s\u0103 pl\u0103teasc\u0103 integral.<\/p>\n
\u201eSolu\u021bii\u201d sau risc major?<\/p>\n
Pe l\u00e2ng\u0103 conversia datoriei \u00een medicamente, Voiculescu propune \u0219i:<\/p>\n
investi\u021bii \u00een infrastructura medical\u0103<\/p>\n
studii clinice \u00een Rom\u00e2nia<\/p>\n
mecanisme de tip \u201eDebt2Health\u201d<\/p>\n
\u00cen plus, cere oprirea dob\u00e2nzilor \u0219i e\u0219alonarea pl\u0103\u021bii, avertiz\u00e2nd c\u0103 fiecare zi de \u00eent\u00e2rziere cost\u0103 p\u00e2n\u0103 la 150.000 de euro.<\/p>\n
Totu\u0219i, ideea central\u0103 r\u0103m\u00e2ne controversat\u0103: plata datoriei prin introducerea accelerat\u0103 a unor produse farmaceutice ridic\u0103 \u00eentreb\u0103ri legate de transparen\u021b\u0103, siguran\u021b\u0103 \u0219i interesul real al pacien\u021bilor.<\/p>\n
Contextul mai larg<\/p>\n
Rom\u00e2nia nu este singura \u00een aceast\u0103 situa\u021bie. Alte state europene au datorii similare c\u0103tre Pfizer, \u00eens\u0103 abord\u0103rile difer\u0103.<\/p>\n
Voiculescu mizeaz\u0103 pe faptul c\u0103 gigantul farmaceutic ar accepta o astfel de \u00een\u021belegere pentru a evita un impact negativ de imagine \u00een Europa.\n<\/p><\/div>\n
[analyse_source url=”https:\/\/4media.info\/vlad-voiculescu-vrea-sa-testeze-pe-romani-medicamente-inovatoare-de-la-pfizer-pentru-procesul-pierdut\/”]<\/p>\n","protected":false},"excerpt":{"rendered":"
[analyse_image type=”featured” src=”https:\/\/4media.info\/wp-content\/uploads\/2021\/04\/vlad-voiculescu-04.042.jpg”] Vlad Voiculescu vine cu \u201esolu\u021bia\u201d pentru datoria la Pfizer: medicamente \u201einovatoare\u201d \u00een loc de bani Fostul ministru al S\u0103n\u0103t\u0103\u021bii, Vlad Voiculescu, propune o variant\u0103 controversat\u0103 pentru achitarea datoriei de aproximativ 600 de milioane de euro c\u0103tre Pfizer: nu bani, ci medicamente \u201einovatoare\u201d pentru pacien\u021bii rom\u00e2ni. Declara\u021bia ridic\u0103 semne serioase de \u00eentrebare, \u00een […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89],"tags":[99,226],"class_list":["post-1890031","post","type-post","status-publish","format-standard","hentry","category-romania","tag-4media-info","tag-crawlmanager"],"_links":{"self":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/1890031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1890031"}],"version-history":[{"count":0,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/1890031\/revisions"}],"wp:attachment":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1890031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1890031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1890031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}